U.S. Ophthalmic Drugs Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Ophthalmic Drugs Market
- ✓Market Size 2024: USD 12.4 billion
- ✓Market Size 2032: USD 18.7 billion
- ✓CAGR: 5.3%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock Biosimilar Supply Early: Buyers and biosimilar investors should secure multi-year aflibercept and bevacizumab supply agreements by 2026, before Part B negotiated pricing reshapes intravitreal margins from 2028. Franchise viability through 2032 depends on that contract visibility.
Ophthalmic Drugs in the United States: Market Overview
The U.S. ophthalmic drugs market was valued at USD 12.4 billion in 2024 and is forecast to reach USD 18.7 billion by 2032. Demand splits across three channels: physician-administered intravitreal biologics billed under Medicare Part B, self-administered topical products dispensed through Part D pharmacies, and hospital-based surgical adjuncts. Private manufacturers have led product innovation, while federal payment rules have set commercial boundaries.
Government has dominated pricing and access rather than development. The Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, created the generic entry framework behind topical glaucoma products. The Biologics Price Competition and Innovation Act of 2009 created the biosimilar pathway now contesting Eylea. Private biotechs have led gene and cell therapy development, while the National Eye Institute funds foundational retinal research.
Policy-Driven Growth in U.S. Eye Medicines
The Biologics Price Competition and Innovation Act created the abbreviated biosimilar approval pathway that FDA's Center for Drug Evaluation and Research uses for aflibercept and bevacizumab-based products. Section 11403 of the Inflation Reduction Act of 2022 pays qualifying Part B biosimilars average sales price plus eight percent through 2027. Physician practices capture that spread, which lowers effective cost per injection and widens treatment-naive patient eligibility.
The Orphan Drug Act of 1983 grants seven years of market exclusivity, and Internal Revenue Code section 45C credits 25 percent of qualified clinical testing costs for orphan indications. Inherited retinal disease programmes depend on these incentives. The Inflation Reduction Act also caps Medicare Part D out-of-pocket spending at USD 2,000 from 2025, improving adherence to chronic topical glaucoma regimens among seniors.
Regulatory Barriers and Compliance Costs
FDA's Center for Drug Evaluation and Research reviews ophthalmic applications under PDUFA VII, which runs through September 2027 and sets a ten-month standard review after a 60-day filing period. Products must satisfy current good manufacturing practice under 21 CFR Parts 210 and 211. The Drug Supply Chain Security Act requires interoperable electronic product tracing, which every ophthalmic stock keeping unit must now carry.
Compounding creates the sharpest local friction. Repackaged bevacizumab syringes for intravitreal use fall under Section 503B of the Federal Food, Drug, and Cosmetic Act, overseen by FDA and state boards of pharmacy. Outsourcing facilities must meet USP chapter 797 sterility standards, and state-by-state licensing adds months of delay and recurring inspection cost. Manufacturers also submit quarterly ASP data to CMS, a reporting burden small firms struggle to absorb.
Policy-Created Opportunities in American Eye Care
Biosimilar aflibercept represents the first opportunity. Section 11403's ASP-plus-eight-percent add-on, combined with the interchangeability pathway FDA is simplifying, makes intravitreal biosimilars commercially attractive for practices that absorb reimbursement spread. Manufacturers able to secure BPCIA approval by 2027 capture the add-on window, which closes after that year.
Orphan gene therapies for inherited retinal disease form the second opportunity, supported by the Orphan Drug Act's exclusivity and the 25 percent section 45C credit. The Department of Veterans Affairs offers a third route through Federal Supply Schedule contracts administered by its Office of Acquisition, Logistics, and Construction, where bulk ophthalmic purchasing favours manufacturers with national distribution.
Market at a Glance
| Metric | Detail |
|---|---|
| Market Size 2024 | USD 12.4 billion |
| Market Size 2032 | USD 18.7 billion |
| Growth Rate (CAGR) | 5.3% |
| Most Critical Decision Factor | Medicare Part B reimbursement rate and biosimilar net pricing |
| Largest Region | South Region (U.S. Census Bureau) |
| Competitive Structure | Concentrated branded retina and surgical leaders with fragmented generic tail |
Leading Market Participants
- Alcon
- Bausch + Lomb
- Regeneron Pharmaceuticals
- Genentech
- Novartis
- AbbVie
- Santen Pharmaceutical
- Ocular Therapeutix
- Harrow
- Sun Pharmaceutical Industries
Regulatory and Policy Environment
The Federal Food, Drug, and Cosmetic Act of 1938, as amended, governs ophthalmic drug approval, labelling, and manufacturing, with FDA's Center for Drug Evaluation and Research as primary administrator. PDUFA VII sets user-fee-funded review timelines through 2027. The Anti-Kickback Statute, 42 U.S.C. section 1320a-7b(b), and the Physician Payments Sunshine Act, administered through CMS Open Payments, restrict manufacturer benefits to ophthalmologists who administer injectables, with disclosure required for each payment above USD 10.
Upcoming changes will reshape compliance. PDUFA VIII negotiations must conclude before reauthorization in September 2027. The first Part B selection list for 2028 negotiated prices is due by February 1, 2026, and Part D cycle prices take effect in 2027. Compared with the European Medicines Agency's centralised procedure under Regulation (EC) No 726/2004, the U.S. system carries user-fee timelines alongside price-negotiation exposure absent in most European markets.
Long-Term Policy Outlook for Ophthalmic Medicines in the United States
By 2032 the Part B negotiation regime will operate on intravitreal biologics, following selection for 2028 pricing. The ASP-plus-eight-percent biosimilar add-on expires after 2027, so manufacturers will rely on net price competition rather than reimbursement premiums. FDA's June 2024 draft guidance removing comparative switching studies for biosimilar interchangeability will accelerate pharmacy-level substitution.
PDUFA VIII, covering fiscal years 2028 through 2032, will define review timelines for ophthalmic applications across the forecast window. Medicare Advantage and Part D plans will shift toward biosimilar formulary preference, reshaping retail share in topical and implant categories. Gene therapy reimbursement for inherited retinal disease will require CMS coverage determinations, establishing a durable pricing framework for orphan ophthalmic products.
Frequently Asked Questions
Market Segmentation
- Retina
- Glaucoma
- Dry Eye Disease
- Anterior Segment Surgery
- Allergic Conjunctivitis
- Anti-VEGF Biologics
- Biosimilars
- Topical Small Molecules
- Sustained-Release Implants
- Gene Therapies
- Physician Office Administration
- Retail Pharmacies
- Hospital Outpatient Pharmacies
- Mail-Order Specialty Pharmacies
- Veterans Affairs Pharmacies
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.